Completed OBSERVATIONAL NCT01618734

Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.

Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP).

Sponsor: Henri Mondor University Hospital

Conditions Immune Thrombocytopenia Thrombopoietin Receptor Agonist

Updated 6 times since 2017 Last updated: Jun 12, 2012 Started: Jan 31, 2012 Primary completion: Jun 30, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Immune Thrombocytopenia and Thrombopoietin Receptor Agonist and is currently completed. Henri Mondor University Hospital leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henri Mondor University Hospital
Paris 12 Val de Marne University

Data source: Henri Mondor University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.